Freya Biosciences

Freya Biosciences is pioneering a new class of microbial immunotherapies targeting the immune drivers of reproductive system diseases. The company has built a proprietary data platform integrating multi-omic analyses from clinical trials to identify and develop treatments for conditions such as IVF failure, endometriosis-associated infertility, and preterm birth. Backed by premier investors and led by a team with a strong track record in drug development and microbiome science, Freya is advancing its pipeline through strategic clinical partnerships. Its core hypothesis is that restoring a healthy microbiome can resolve local inflammation and improve reproductive health outcomes.

Integrated human-first data platform combining quantitative microbiome sequencing, proteomic/transcriptomic immune profiling (450+ and 600+ markers, respectively), and clinical outcomes data from over 600 women to discover and develop microbial immunotherapies.

The women's health microbiome space is emerging but growing. Competition includes other biotechs exploring vaginal microbiome transplants or defined microbial consortia, though few have advanced as far clinically. Freya's deep multi-omic data platform and specific focus on immune modulation are key differentiators.